ClinicalTrials.gg
CompletedNCT03923959TAHFTUpdated Oct 10, 2024Results posted

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

A Phase 3 interventional study of Tranexamic Acid Injectable Solution and Placebo in Hip Fractures, sponsored by Lancaster General Hospital. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Lancaster General Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.

Enrollment
2nd of 21
283 · median 120
Started
2020
with 2 others
Phase 3
4 of 22
none open now
Registered
17th of 22
by date

Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 17th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Tranexamic Acid in Hip Fractures, or all of them as a file.
02

Study summary

The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.

Read the detailed description

A significant portion of the geriatric hip fracture population have comorbidities including chronic kidney disease, congestive heart failure, ischemic heart disease, stroke, etc. These patients may be anemic prior to the surgery, and are at increased risk for further blood loss as a result of the fracture and surgical operation. However, intra-operative or post-operative blood transfusions also increase the risk of renal and cardiac complications in this population.

Tranexamic acid (TXA) is an anti-fibrinolytic medication that has transformed total joint replacement management regarding blood loss prevention. Geriatric patients requiring emergent hip fracture repair may significantly benefit from routine administration of TXA prior to the procedure to decrease the risk of blood loss. Thus, treatment may further reduce the percentage of patients who experience blood transfusions and complications associated with transfusions.

The investigators will examine if administration of TXA prior to incision in the geriatric hip fracture patient population decreases the risk of intra-operative or post-operative blood transfusions compared to placebo.

03

Conditions studied

  • Hip Fractures

Keywords

  • Blood
  • Transfusion
  • Hip
  • Fracture
  • Surgery
  • Replacement
  • Trauma
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written
  2. Age > or = to 65 years
  3. Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric regions
  4. Indication for one of the following surgical interventions: hemiarthroplasty, total hip replacement, sliding plate and screw fixation, or intramedullary fixation

Exclusion criteria

Exclusion Criteria:

  1. Indication for closed reduction or percutaneous screw
  2. Allergy to TXA
  3. Cerebrovascular accident/stroke, active coronary disease/myocardial infarction, or deep vein thrombosis/pulmonary emboli within one (1) month of the fracture
  4. Presence of hypercoaguable disorder, including cancer (active disease), elevated blood homocysteine levels, antiphospholipid antibody syndrome and inherited protein deficiencies (antithrombin III, factor V Leiden, protein S \& C deficiencies, prothrombin gene mutation)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
283 participants (actual)

Study arms

  • Active comparator
    Intervention

    100 cc normal saline with 1g of tranexamic acid in solution

    Drug: Tranexamic Acid Injectable Solution

  • Placebo comparator
    Placebo

    100 cc normal saline

    Other: Placebo

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 cc normal saline mixed with 1g of tranexamic acid in solution

    Also known as: Cyklokapron

  • OtherPlacebo

    100 cc normal saline

06

What researchers measure

Primary outcomes

  1. Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.

    Count of participants with acute post-operative transfusion of packed red blood cells along with the corresponding 95% CI.

    Time frame: 3 Months

Secondary outcomes

  1. Complication Rate

    Determine if participants randomized to TXA experienced increased risk of complications compared to placebo. Complications include number of deep vein thrombosis events, pulmonary emboli events, myocardial infarction events, and cerebral vascular events within 12 weeks post hip fracture surgery.

    Time frame: 3 Months

  2. Hospital Readmission

    Determine differences between the groups in 30 day readmission rates.

    Time frame: 30 Days

  3. Mortality Rate

    Death within 90 days post hip surgery

    Time frame: 90 Days

  4. Length of Stay

    Length of stay immediately post study intervention/surgery for hip fracture

    Time frame: From date of study intervention/surgery for hip fracture until the date of discharge or date of death from any cause, whichever came first, assessed up to 34 months.

07

Results

Posted Oct 10, 2024

Participant flow

Participant flow — Overall Study
MilestoneInterventionPlacebo
Started146138
Completed7368
Not completed7370
Withdrew: Death1612
Withdrew: Lost to follow-up5656
Withdrew: Withdrawal by subject11
Withdrew: Participant enrolled twice for separate hip fractures - one enrollment removed.01

Outcome measures

PrimaryCount of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.

Count of participants with acute post-operative transfusion of packed red blood cells along with the corresponding 95% CI.

Time frame:
3 Months
Reported as:
Count of participants · Participants
Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.
ParticipantsInterventionPlacebo
Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.118111
Statistical analysis
  • Intervention vs Placebo · Regression, Logistic · p = 0.966 · Odds ratio (or): 1.013 · 95% CI 0.5597 to 1.834
SecondaryComplication Rate

Determine if participants randomized to TXA experienced increased risk of complications compared to placebo. Complications include number of deep vein thrombosis events, pulmonary emboli events, myocardial infarction events, and cerebral vascular events within 12 weeks post hip fracture surgery.

Time frame:
3 Months
Reported as:
Count of participants · Participants
Complication Rate
ParticipantsInterventionPlacebo
Complication Rate4330
Statistical analysis
  • Intervention vs Placebo · Chi-squared · p = 0.183 (a priori threshold for statistical significance was the standard α = 0.05.)
SecondaryHospital Readmission

Determine differences between the groups in 30 day readmission rates.

Time frame:
30 Days
Reported as:
Count of participants · Participants
Hospital Readmission
ParticipantsInterventionPlacebo
Hospital Readmission118
Statistical analysis
  • Intervention vs Placebo · Chi-squared · p = 0.729 (a priori threshold for statistical significance was the standard α = 0.05.)
SecondaryMortality Rate

Death within 90 days post hip surgery

Time frame:
90 Days
Reported as:
Count of participants · Participants
Mortality Rate
ParticipantsInterventionPlacebo
Mortality Rate1511
Statistical analysis
  • Intervention vs Placebo · Chi-squared · p = 0.655 (a priori threshold for statistical significance was the standard α = 0.05)
SecondaryLength of Stay

Length of stay immediately post study intervention/surgery for hip fracture

Time frame:
From date of study intervention/surgery for hip fracture until the date of discharge or date of death from any cause, whichever came first, assessed up to 34 months.
Reported as:
Mean · days
Length of Stay
daysTreatmentPlacebo
Length of Stay5 ± 4.14.8 ± 3.8
Statistical analysis
  • Treatment vs Placebo · t-test, 2 sided · p = 0.7832 (a priori threshold for statistical significance was the standard α = 0.05.)

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention16/146 (11%)3/146 (2.1%)69/146 (47.3%)
Placebo12/137 (8.8%)1/137 (0.7%)57/137 (41.6%)
Most frequent serious events
Most frequent serious events
EventInterventionPlacebo
DeathGeneral disorders0/1461/137
Hyperglycemia (worsening of condition -> death)Endocrine disorders1/1460/137
Acute infarct in R parietal region (pt released on hospice)Vascular disorders1/1460/137
Post-operative respiratory failure with hypercarbiaRespiratory, thoracic and mediastinal disorders1/1460/137
Most frequent other events
Most frequent other events
EventInterventionPlacebo
MildGeneral disorders44/14638/137
ModerateGeneral disorders25/14619/137

Baseline characteristics

Participant enrolled twice for separate hip fractures - one enrollment removed.

Age, Continuous
Age, Continuous(years)InterventionPlaceboTotal
Mean88.2 ± 1186.0 ± 8.787.2 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)InterventionPlaceboTotal
Female105106211
Male413172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)InterventionPlaceboTotal
Hispanic or Latino213
Not Hispanic or Latino144136280
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InterventionPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White142134276
More than one race000
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(participants)InterventionPlaceboTotal
United States146137283
08

Study locations

1 site
  • Lancaster General Heatlh / Penn Medicine
    Lancaster, Pennsylvania 17602, United States
09

References and documents

Publications

  • Farrow LS, Smith TO, Ashcroft GP, Myint PK. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol. 2016 Dec;82(6):1458-1470. doi: 10.1111/bcp.13079. Epub 2016 Sep 20. PubMed 27492116 ↗
  • Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. PubMed 20190103 ↗
  • Ponnusamy KE, Kim TJ, Khanuja HS. Perioperative blood transfusions in orthopaedic surgery. J Bone Joint Surg Am. 2014 Nov 5;96(21):1836-44. doi: 10.2106/JBJS.N.00128. PubMed 25378512 ↗
  • Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 Mar;123(5):687-96. doi: 10.1016/j.thromres.2008.09.015. Epub 2008 Nov 12. PubMed 19007970 ↗
  • Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Noveck H, Strom BL. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996 Oct 19;348(9034):1055-60. doi: 10.1016/S0140-6736(96)04330-9. PubMed 8874456 ↗
  • Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis. J Arthroplasty. 2018 Oct;33(10):3083-3089.e4. doi: 10.1016/j.arth.2018.06.023. Epub 2018 Jun 27. PubMed 30007789 ↗
  • Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty. 2018 Oct;33(10):3070-3082.e1. doi: 10.1016/j.arth.2018.03.031. Epub 2018 Mar 22. PubMed 29699826 ↗
  • Carling MS, Jeppsson A, Eriksson BI, Brisby H. Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. J Orthop Surg Res. 2015 Mar 28;10:48. doi: 10.1186/s13018-015-0188-6. PubMed 25889413 ↗
  • Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, Tang S, Logishetty R, Vaghela M, McPartlin L, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013 Nov 6;95(21):1969-74. doi: 10.2106/JBJS.L.00908. PubMed 24196467 ↗
  • Alshryda S, Mason J, Vaghela M, Sarda P, Nargol A, Maheswaran S, Tulloch C, Anand S, Logishetty R, Stothart B, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). J Bone Joint Surg Am. 2013 Nov 6;95(21):1961-8. doi: 10.2106/JBJS.L.00907. PubMed 24196466 ↗
  • Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000 Jun;71(3):250-4. doi: 10.1080/000164700317411834. PubMed 10919295 ↗
  • Rajesparan K, Biant LC, Ahmad M, Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br. 2009 Jun;91(6):776-83. doi: 10.1302/0301-620X.91B6.22393. PubMed 19483232 ↗
  • North WT, Mehran N, Davis JJ, Silverton CD, Weir RM, Laker MW. Topical vs Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty: A Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2016 May;31(5):1022-6. doi: 10.1016/j.arth.2015.11.003. Epub 2015 Nov 10. PubMed 26703193 ↗
  • Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ. Oral and Intravenous Tranexamic Acid Are Equivalent at Reducing Blood Loss Following Total Hip Arthroplasty: A Randomized Controlled Trial. J Bone Joint Surg Am. 2017 Mar 1;99(5):373-378. doi: 10.2106/JBJS.16.00188. PubMed 28244907 ↗
  • Imai N, Dohmae Y, Suda K, Miyasaka D, Ito T, Endo N. Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplasty. 2012 Dec;27(10):1838-43. doi: 10.1016/j.arth.2012.04.024. Epub 2012 Jun 14. PubMed 22704229 ↗
  • Fillingham YA, Kayupov E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ. The James A. Rand Young Investigator's Award: A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Total Knee Arthroplasty: The Same Efficacy at Lower Cost? J Arthroplasty. 2016 Sep;31(9 Suppl):26-30. doi: 10.1016/j.arth.2016.02.081. Epub 2016 Mar 19. PubMed 27113948 ↗
  • Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG, Perez-Chrzanowska H, Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014 Dec 3;96(23):1937-44. doi: 10.2106/JBJS.N.00060. PubMed 25471907 ↗
  • Levine BR, Haughom BD, Belkin MN, Goldstein ZH. Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014 Sep;29(9 Suppl):186-8. doi: 10.1016/j.arth.2014.01.038. Epub 2014 May 27. PubMed 24997651 ↗
  • Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. PubMed 18929686 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Dec 2022, 34 months.

Results were first posted in Oct 2024, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2019
First posted
Apr 23, 2019
StartActual
Feb 1, 2020
Primary completionActual
Dec 9, 2022
CompletionActual
Dec 9, 2022
Results first posted
Oct 10, 2024
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03923959
Lead sponsor
Lancaster General Hospital
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Feb 1, 2020
Primary completion
Dec 9, 2022
Completion
Dec 9, 2022
Results posted
Oct 10, 2024
Last update
Oct 10, 2024

Study contacts

Gregory Tocks, DO
principal investigator · Penn Medicine / Lancaster General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion